Blueprint Medicines Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
767
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$9.5B
Blueprint Medicines General Information
Description
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Contact Information
Website
www.blueprintmedicines.com(Operating Subsidiary)
Corporate Office
- 45 Sidney Street
- Cambridge, MA 02139
- United States
Corporate Office
- 45 Sidney Street
- Cambridge, MA 02139
- United States
Blueprint Medicines Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Merger/Acquisition | 18-Jul-2025 | $9.5B | Completed | Generating Revenue | ||
| 14. General Corporate Purpose | 30-Jun-2022 | Completed | Generating Revenue | |||
| 13. PIPE | 13-Jul-2020 | Completed | Generating Revenue | |||
| 12. 2PO | 23-Jan-2020 | Completed | Generating Revenue | |||
| 11. 2PO | 29-Mar-2019 | Completed | Generating Revenue | |||
| 10. Secondary Transaction - Open Market | 31-Mar-2018 | Completed | Generating Revenue | |||
| 9. 2PO | 15-Dec-2017 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Open Market | 06-Jun-2017 | Completed | Generating Revenue | |||
| 7. Secondary Transaction - Open Market | 31-Mar-2017 | $405M | Completed | Generating Revenue | ||
| 6. 2PO | 13-Dec-2016 | $144M | $405M | Completed | Generating Revenue |
Blueprint Medicines Comparisons
Industry
Financing
Details
Blueprint Medicines Competitors (90)
One of Blueprint Medicines’s 90 competitors is Arcus Biosciences, a Formerly VC-backed company based in Hayward, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| AB Science | Formerly Accelerator/Incubator backed | Paris, France | ||||
| AVEO Oncology | Formerly VC-backed | Boston, MA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA |
Blueprint Medicines Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Blueprint Medicines Patents
Blueprint Medicines Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026217690-A1 | Substituted pyrrolopyrimidine cyclin-dependent kinase 4 degraders | Pending | 09-Apr-2025 | ||
| WO-2026198737-A2 | Kras inhibitors | Pending | 20-Mar-2025 | ||
| WO-2026198401-A1 | Quinazolin-2-ylamino cyclin-dependent kinase 2 degraders | Pending | 17-Mar-2025 | ||
| WO-2026183379-A1 | Combination therapies for treating asthma | Pending | 28-Feb-2025 | ||
| US-20260250266-A1 | Heterocyclic pan-kras inhibitors | Pending | 11-Feb-2025 | C07D401/14 |
Blueprint Medicines Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Blueprint Medicines Former Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aquilo Capital Management | Hedge Fund | Minority | ||
| BVF Partners | Hedge Fund | Minority | ||
| Boxer Capital | Corporate Venture Capital | Minority | ||
| Casdin Capital | Venture Capital | Minority | ||
| Cowen Healthcare Investments | Venture Capital | Minority |
Blueprint Medicines Investments & Acquisitions (2)
Blueprint Medicines’s most recent deal was a Early Stage VC with IDRx for . The deal was made on 28-Apr-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| IDRx | 28-Apr-2022 | Early Stage VC | Drug Discovery | ||
| Lengo Therapeutics | 30-Dec-2021 | Merger/Acquisition | Drug Discovery |
Blueprint Medicines ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
26.43 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Blueprint Medicines Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Blueprint Medicines (US Rights of Gavreto) |
Blueprint Medicines FAQs
-
When was Blueprint Medicines founded?
Blueprint Medicines was founded in 2008.
-
Where is Blueprint Medicines headquartered?
Blueprint Medicines is headquartered in Cambridge, MA.
-
What is the size of Blueprint Medicines?
Blueprint Medicines has 767 total employees.
-
What industry is Blueprint Medicines in?
Blueprint Medicines’s primary industry is Drug Discovery.
-
Is Blueprint Medicines a private or public company?
Blueprint Medicines is a Private company.
-
What is the current valuation of Blueprint Medicines?
The current valuation of Blueprint Medicines is .
-
What is Blueprint Medicines’s current revenue?
The current revenue for Blueprint Medicines is .
-
How much funding has Blueprint Medicines raised over time?
Blueprint Medicines has raised $2.14B.
-
Who are Blueprint Medicines’s investors?
Aquilo Capital Management, BVF Partners, Boxer Capital, Casdin Capital, and Cowen Healthcare Investments are 5 of 20 investors who have invested in Blueprint Medicines.
-
Who are Blueprint Medicines’s competitors?
Arcus Biosciences, Gilead, AB Science, AVEO Oncology, and Amgen are some of the 90 competitors of Blueprint Medicines.
-
When was Blueprint Medicines acquired?
Blueprint Medicines was acquired on 18-Jul-2025.
-
Who acquired Blueprint Medicines?
Blueprint Medicines was acquired by Sanofi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
